Clinical Trials Logo

Bell Palsy clinical trials

View clinical trials related to Bell Palsy.

Filter by:

NCT ID: NCT05945615 Enrolling by invitation - Blepharoptosis Clinical Trials

Oxymetazoline Drops for Acquired Blepharoptosis From Synkinesis

Start date: January 11, 2024
Phase: Phase 3
Study type: Interventional

After an episode of facial paralysis, as nerves recover, they aberrantly regenerate and send additional branches to the incorrect muscles in addition to the intended muscle. This leads to what is known as Aberrant Regeneration Syndrome, Post-paralysis Synkinesis, or Nonflaccid Facial Paralysis. It is characterized by poor facial symmetry and function, hypertonic facial muscles at rest, and abnormal facial movements. One sequela is acquired blepharoptosis causing a smaller ocular aperture, visual field obstruction, cosmetic deformity, and abnormal periocular spasms. This study aims to evaluate an FDA approved medication for acquired blepharoptosis due to synkinesis/hyperkinesis as an adjunct to treatment.

NCT ID: NCT05891106 Completed - Corneal Ulcer Clinical Trials

AONDA Therapeutic Indication Study I

Start date: June 28, 2023
Phase:
Study type: Observational

This study will be used to support assessment of AIR OPTIX® NIGHT & DAY® AQUA (AONDA) Soft Contact Lenses' safety and performance in accordance with updated European Union Medical Device Regulation (EU MDR) requirements.

NCT ID: NCT05855928 Recruiting - Bell Palsy Clinical Trials

Effectiveness of ES and MT VS ES and PNF Technique Among Bells Palsy Patients

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

To determine the effectiveness of electrical stimulation with MIME therapy versus electrical stimulation with PNF technique for improving strength & restoring lost motor function in the patients of Bell's palsy

NCT ID: NCT05846217 Completed - Clinical trials for Laser Treatment Relieve Symptoms of Chronic Bell's Palsy

Bell's Palsy With a Duration of Greater Than 8 Weeks Treated With Multiwave Locked System Intervention

Start date: May 1, 2021
Phase: N/A
Study type: Interventional

OBJECTIVE: To determine whether photobiomodulation therapy by class IV Multiwave Locked System laser treatment could relieve symptoms in patients with Bell's palsy with a duration of greater than 8 weeks. METHODS AND METHODS: This randomized controlled trial from May 2021 to April 2023. Patients were eligible who had Bell's palsy with a duration of greater than 8 weeks on out-patient department of otorhinolaryngology in Beijing Tongren Hospital. The photobiomodulation group received class IV Multiwave Locked System laser treatment for 3 times per weeks, a total of 6 months. The control group received the same Multiwave Locked System treatment procedure except the laser parameter. The primary outcome measures comprised House-Brackmann facial nerve grading system, Sunnybrook facial grading system, Facial Clinimetric Evaluation Scale. Secondary outcome measures comprised Electroneurography, Electromyography, and the Blink Reflex.

NCT ID: NCT05821075 Recruiting - Bell Palsy Clinical Trials

Efficacy of Prednisolone Versus Cerebrolysin in the Treatment of Bell's Palsy

Start date: April 24, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

Bell's palsy, a peripheral facial nerve paresis, is the most common disorder of the facial nerve and one of the most common mononeuropathies. Many patients with Bell's palsy will develop some complications such as synkinesis, crocodile tears and 'sweating' of the ear while eating Commonly used medications to treat Bell's palsy is Corticosteroids Cerebrolysin stimulates the regeneration of the nervous tissue with protective action we aim to study the efficacy of cerebrolycin in Bell's palsy

NCT ID: NCT05707091 Recruiting - Bell's Palsy Clinical Trials

Low Laser Therapy on Facial Motor Functions Function and Synkinesis in Patients With Bell's Palsy

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

To determine the effects of low-level laser therapy on facial motor functions and synkinesis in patients with bell's palsy

NCT ID: NCT05679752 Completed - Bell Palsy Clinical Trials

Effects of Massage Therapy and Facial PNF in Early Bell's Palsy

Start date: September 21, 2022
Phase: N/A
Study type: Interventional

Effects of Massage therapy and Facial PNF in early Bell's palsy

NCT ID: NCT05585346 Completed - Bell's Palsy Clinical Trials

Photobiomodulation Therapy for Idiopathic Facial Paralysis

Start date: January 1, 2021
Phase: N/A
Study type: Interventional

Objective: Bell's palsy is characterized by acute, unilateral onset that compromises function and esthetics, exerting a considerable impact on the social, professional, and psychological aspects of the lives of affected individuals. Without treatment, 30% of patients with complete paralysis will not completely recover. Therefore, shortening the recovery time will accelerate the recovery process leading to better results. The objective of this study was to determine whether photobiomodulation therapy with laser acupuncture therapy could relieve symptoms in patients with Bell's palsy. Methods: This study was an open-label, randomized controlled trial including 96 patients that undergoing Bell's palsy. All the patients received oral vitamin B1. Patients were assigned to the laser acupuncture (LA) group and control group, with 102 patients in each group. LA group were received 4 weeks of Laser treatment (3 times per week), while control group were received sham laser treatment. Clinical outcome measure comprised the House-Brackmann grading system, Facial Clinimetric Evaluation Scale (FaCE), Sunnybrook facial grading scale (SBFG), and electrophysiological testing, including Electroneuronography (ENoG), Electromyography (EMG) and Blink Reflex. All the measurements were collected at the first day and at the end of study. All reported P values were two-sided and were declared statistically significant when less than 0.05.

NCT ID: NCT05585333 Completed - Facial Paralysis Clinical Trials

Photobiomodulation Therapy Treatment on Facial Paralysis

Start date: January 1, 2021
Phase: N/A
Study type: Interventional

Objective: Facial paralysis can be caused by a variety of etiological factors, complete palsy continues for two months, the chance of full recovery is reduced to zero. The aim of this study was to evaluate the effectiveness of photobiomodulation therapy (PBMT) in the in patients undergoing facial paralysis over 8 weeks. Methods: This study was an open-label, not concurrent control study including 54 patients that underwent facial paralysis over 8 weeks. Patients were assigned to the PBMT group and control group, with 27 patients in each group. Laser treatments were applied 3 days a week after recruited. PBMT was delivered using a class IV Multi-wave Locked System that combines with a simultaneous 808 nm continuous emission and 905 nm pulse emission and the maximum peak power was 25 W. Clinical outcome measure comprised the House-Brackmann grading system, Facial Clinimetric Evaluation Scale (FaCE), Sunnybrook facial grading scale (SBFG), and electrophysiological testing, including Electroneuronography (ENoG), Electromyography (EMG) and Blink Reflex. All the measurements were collected at the first day and at the end of study. All reported P values were two-sided and were declared statistically significant when less than 0.05.

NCT ID: NCT05582915 Recruiting - Bell Palsy Clinical Trials

Screening for Prognostic Biomarkers of Severe Bell's Palsy in Adults

BIOFIPS
Start date: January 3, 2023
Phase:
Study type: Observational

Bell's palsy (idiopathic peripheral facial palsy) is the most common cause of facial palsy, which is related to the inflammation of the facial nerve, possibly induced by herpesvirus reactivation. Its first-line treatment comprises corticosteroids, antiviral therapy and physiotherapy. In most severe cases (grade IV to VI on House-Brackmann scale), facial motricity may remain altered or develop synkinesis or post-paralytic spasm, thus tremendously affecting quality of life. To avoid potential complications, surgical facial nerve decompression could be proposed. To date, however, there are no means to predict if Bell's palsy will evolve with any complications or if the patient will recover entirely. Thus, the invasive facial nerve decompression is equally proposed to subjects who will develop the consequences as well as to subjects able to restore without surgical treatment. This study proposes to search for prognostic blood biomarkers related to the Bell's palsy recovery pattern. Adult patients with severe Bell's palsy will be proposed to have a blood sampling for proteomic analysis in the early stage of the disease. Then 125 biomarkers on a Peptiquantâ„¢ kit will be analysed by mass spectrometry, and prognostic biomarkers will be selected regarding to the clinical recovery of Bell's palsy